Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT).
David Ira Rosenthal
Honoraria - Bristol-Myers Squibb; ImClone Systems
Research Funding - Merck Serono
Paul M. Harari
No relevant relationships to disclose
Jordi Giralt
No relevant relationships to disclose
Diana Bell
No relevant relationships to disclose
David Raben
No relevant relationships to disclose
Joyce Liu
Employment or Leadership Position - Merck Serono
Jeltje Schulten
Employment or Leadership Position - Merck KGaA
K. Kian Ang
No relevant relationships to disclose
James A. Bonner
Consultant or Advisory Role - Bristol-Myers Squibb; Lilly
Honoraria - Bristol-Myers Squibb; Lilly
Research Funding - Bristol-Myers Squibb